S-1 + bevacizumab + oxaliplatin

S-1 + bevacizumab + oxaliplatin is a combination chemotherapy regimen used primarily in the treatment of metastatic colorectal cancer. - **S-1** is an oral fluoropyrimidine derivative composed of tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU levels), and oteracil (to reduce gastrointestinal toxicity). It acts as an antimetabolite interfering with DNA synthesis. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks and inhibits DNA replication and transcription. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. This combination has been studied as first-line therapy for metastatic colorectal cancer, showing non-inferiority to other standard regimens such as mFOLFOX6 plus bevacizumab in terms of progression-free survival[3]. The addition of bevacizumab to oxaliplatin-based chemotherapy improves progression-free survival but may not significantly improve overall response rates or overall survival[1][3][4]. Reduced-dose combinations have also shown efficacy with lower toxicity in older or vulnerable patients[2].

Other names

SOX+BevS-1/oxaliplatin plus bevacizumab